

Prevalence of A6224G Insulin Receptor Substrate-1 and Mitochondrial DNA tRNA)Leu(UUR) 3243 Polymorphisms in Diabetes Mellitus Patients in Saudi Arabia

^{1,2}Nabil S. Awad, ^{1,3}Adel E. El-Tarras, ⁴Talal A. Almalki,
⁵Abdelhameed Alghamdi, ^{1,6}Ayman M. Sabry and ⁴Dalal Nemenqani

¹Biotechnology and Genetic Engineering Unit, Scientific Research Deanship, Taif University, KSA

²Ain Shams University Center for Genetic Engineering and Biotechnology (ACGEB),
Ain Shams University, Cairo, Egypt

³Genetics Department, Faculty of Agriculture, Cairo University, Cairo, Egypt

⁴College of Medicine, Taif University, KSA

⁵Department of Ophthalmology, Faculty of Medicine, Taif University, KSA

⁶Department of Cell Biology, National Research Center, Dokki, Giza, Egypt

Abstract: The prevalence of diabetes is high among the Saudi population and 90% of diabetics suffer from Type II diabetes mellitus (T2DM). Genetic polymorphisms are integral to the development of genetic markers to identify individuals at risk of developing T2DM. These genetic markers could be used for early detection and molecular diagnosis of diabetes. The objective of the present study is to detect the prevalence of A6224G polymorphism within the Insulin receptor substrate-1 (IRS-1) gene and tRNA)Leu(UUR) 3243 polymorphism in mitochondrial DNA among T2DM. Saudi patients. One hundred and six patients were recruited. Genotyping was carried out via PCR-RFLP technique. No patients with tRNA)Leu(UUR) 3243 polymorphisms were found. Three genotypes of A6224G polymorphism were detected. The prevalence of the detected genotypes was (40.6 for AA, 58.5 for AG and 0.94 for GG and). The frequency of A allele was 0.7 and for G allele was 0.3.

Key words: Diabetes • Insulin Receptor Substrate-1 gene • Mitochondrial DNA • PCR-RFLP

INTRODUCTION

Diabetes mellitus (DM) is a heterogeneous group of metabolic disorders characterized by high blood glucose level [1]. Diabetes mellitus is a major public issue due to its high prevalence and long term complications. Worldwide, the number of people with diabetes is increasing due to population growth, aging, urbanization, life style, physical inactivity. The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 [2]. In Saudi Arabia diabetes represents a major clinical and public health problem. The prevalence of diabetes is high among the Saudi population and 90% of diabetics suffer from Type II (T2DM) [3,4]. Growing concern about diabetes worldwide and

particularly the staggering impact the disease is having in the Gulf Region, where the picture is especially alarming. The Co-operation Council for the Arab States of the Gulf (GCC) has some of the highest rates of type II diabetes in the world. Qatar, Bahrain, United Arab Emirates, Saudi Arabia, Kuwait and Oman are of the International Diabetes Federation's 'top10' countries for diabetes prevalence [5]. The anticipated prevalences for diabetes 2010-2030 in the Gulf countries are: United Arab Emirates (UAE) 18.7-21.4%, Kingdom of Saudi Arabia (KSA) 16.8-18.9%, Bahrain 15.4-17.3%, Kuwait 14.6-16.9% and Oman 13.4-14.9% [5, 6].

It is well established that genetic factors play an important role in the development of diabetes mellitus [7]. Genetic polymorphisms are integral to the development of genetic markers to identify individuals at risk of developing such disease [8].

Corresponding Author: Nabil S. Awad, Biotechnology and Genetic Engineering Unit, Scientific Research Deanship, Taif University, KSA, Ain Shams University Center for Genetic Engineering and Biotechnology (ACGEB), Ain Shams University, Cairo, Egypt.

In Saudi Arabia several studies have been conducted to evaluate the association between different diabetes types (Type 1, Type 2 and gestational) with different genes polymorphisms using different molecular genetic approaches [9-14].

Mitochondria play a key role in biogenesis, in glucose metabolism and in adenosine-5-triphosphate (ATP) production, which has been linked to insulin secretion in pancreatic beta cells [15]. Several line of evidences showed numerous mitochondrial DNA mutations were significantly associated with development of diabetes [16-19].

Insulin receptor substrate-1 (IRS-1) is the first substrate of the insulin receptor in the insulin signaling pathway [20]. Due to this central role, the IRS-1 function could be related to the development of T2DM. Almind *et al.* [21] found association between Insulin receptor substrate-1 IRS-1 gene polymorphisms with T2DM.

The aim of the present work is screening for the Insulin receptor substrate-1 (IRS-1) and mitochondrial tRNA^{Leu(UUR)} 3243 polymorphisms among T2DM Saudi patients.

MATERIALS AND METHODS

Patients and Blood Sample Collection: In the present study 106 type 2 diabetes mellitus Saudi patients were recruited and collected from the king Abdul-Aziz specialized hospital, Taif governorate. Whole blood samples of T2DM patients were drawn from a peripheral vein into ethylenediaminetetraacetic acid (EDTA) tubes and stored at -20°C until DNA extraction step.

DNA Extraction: Genomic DNA was extracted from blood samples according to instructions of Blood DNA Preparation Kit (Jena Bioscience; Germany).

The procedure of this kit is consists of three major steps. Blood samples were subjected to the first step in order to cell Lysis. Proteins were precipitated from the lysate with protein precipitation solution. Then, DNA was precipitated and hydrated via ethanol and DNA hydration solution respectively.

Genotyping: PCR amplification and genotyping of Insulin receptor substrate-1 (IRS-1) A6224G and transfer ribonucleic acid tRNA^{Leu(UUR)} 3243 polymorphisms were carried out via PCR-RFLP technique. Amplification of specific targeted DNA fragments was carried out with a total volume of 25 ul consists of 50-70 ng DNA template, 12.5 ul of 2X superhot PCR Master Mix (Bioron; Germany) and 10 Pmol of each used primer. The sequence of each used primer is listed in (Table 1). The PCR program for amplification of tRNA^{Leu(UUR)} was as follow; initial denaturation at 95°C for 3 min, followed by 35 cycles each at 95°C for 1 min, annealing temperature at 55 for 1 min, extension temperature at 72°C for 1.5 min and final extension at 72°C for 10 min. [7]. Amplification of Insulin receptor substrate-1 (IRS-1) gene was carried out with denaturation at 94°C for 3 min. and followed by 35 cycles of 94°C for 45 sec, 58°C for 45 second 72°C for 1 min., final extention at 72°C for 5 min. [8]. The amplified DNA fragments were eletrophoresed with 100 bp ladder marker (Fermentas, Germany) on 10 x 14 cm 1.5%-agarose gel (Bioshop; Canada) for 30 min using Tris-borate-EDTA Buffer. The gels were stained with 0.5 µg/ml of ethidium bromide (Bioshop; Canada), visualized on a UV Transilluminator, photographed using a GeneSnap 4.00- Gene Genius Bio Imaging System (Syngene; Frederick, Maryland, USA).

The amplified DNA fragments specific for A6224G and tRNA^{Leu(UUR)} 3243 polymorphisms within Insulin receptor substrate-1 (IRS-1) gene and mitochondrial gene transfer ribonucleic acid were digested with 2-4 units of

Table 1: Names of studied genes and sequences of used primers

Gene	Target polymorphism	Primers
Insulin receptor substrate-1 (IRS-1)	A6224G	5-CGGTCTTGTAAGGGTAAC-3 5-GAATTCACATTCCTCAAGACA-3
Mitochondrial gene transfer ribonucleic acid	tRNA ^{Leu(UUR)} 3243	5-AGGACAAGAAATAAGGCC-3 5-CACGTTGGCCTTTGCGTA-3

Table 2: Polymorphisms, restriction enzyme and expected digestion fragment size

Target polymorphism	Amplified fragment size	Restriction enzyme	Expected genotypes	Fragment size
A6224G	324bp	<i>NsiI</i>	AA	324
			AG	324+239+85
			GG	239+85
tRNA ^{Leu(UUR)} 3243	294bp	<i>Apal</i>	AA	294
			AG	294+179+115
			GG	179+115

NsiI and *ApaI* restriction enzymes respectively. According to the manufacture instructions specific restriction enzyme 10X buffer in reaction volume of 20ul was used. For each restriction enzyme, incubation temperature and period as well as heat inactivation protocol were optimized and carried out according to manufacturer instructions. The digested DNA fragments were electrophoresed on 2.5% agarose gel stained with ethidium bromide. The gels were visualized on a UV Transilluminator, photographed using a GeneSnap 4.00-Gene Genius Bio Imaging System (Syngene; Frederick, Maryland, USA). The digital image files were analyzed using Gene Tools software from Syngene.

Expected amplified fragment size and genotypes for each studied polymorphisms were illustrated in Table (2). Two DNA fragments and three genotypes could be produced in case of A to G mutation was found in the amplified fragments of studied mtDNA and IRS-1 genes Table (2).

RESULTS

Amplification of A6224G and tRNA^{Leu(UUR)} 3243 polymorphisms within Insulin receptor substrate-1 (IRS-1) gene and Mitochondrial gene transfer ribonucleic acid was carried out. 324bp and 294bp DNA fragments specific for A6224G and tRNA^{Leu(UUR)} 3243 polymorphisms respectively were detected in all used DNA samples Figures (1 and 2).

The resultant (324 and 294bp) DNA fragments were digested with of *NsiI* and *ApaI* respectively.

No patients with the mitochondrial tRNA^{Leu(UUR)} gene mutation at position 3243 were found. Three genotypes of A6224G polymorphism within Insulin receptor substrate-1 (IRS-1) gene after digestion with *NsiI* were observed Figure (3).

The genotypic distribution and allelic frequency of studied polymorphisms were summarized in Table (4).



Fig. 1: PCR amplified DNA fragment (324bp) of A6224G within insulin receptor substrate-1 (IRS-1) gene among diabetic patients




Fig. 2: PCR amplified DNA fragment (294bp) of A3243G polymorphism within mitochondrial tRNA^{Leu(UUR)} gene among diabetic patients




Fig. 3: Electrophoretic banding pattern of amplified DNA fragment 324bp within IRS-1 gene after digestion with *NsiI* restriction enzyme. Lane 1: slandered DNA marker (100bp); lane 2: AA genotype; lane 6: GG genotype; Lane 12: AG genotype

Table 4: Prevalence, genotypes and allele frequencies of A6224G polymorphism

polymorphism	No. of subject	Prevalence %	Allele frequency	
			A	G
GG	1	0.94		
AG	62	58.5	62	2
AA	43	40.6	86	62
Total	106		148 (0.7)	64 (0.3)

DISCUSSION

Insulin receptor substrate-1 (IRS1) gene encodes for substrate of the insulin receptor tyrosine kinase and involved in the signal transduction that characterizes insulin biological activity [8, 22]. So, different studies have been conducted to study the role of IRS1 as a candidate gene for type II diabetes. Several polymorphisms have been described in this gene, Laakso *et al.* [23] used single strand conformation polymorphism to analyze amino acid substitution in noninsulin-dependent diabetes (NIDDM) among Finnish patients and identified three variants that predict amino acid substitution Gly818-Arg, Ser892Gly and Gly971Ar. The most common polymorphism was the Gly971Arg substitution which was found in 11 (9.8%) of 112 NIDDM patients. Almind *et al.* [24] reported that, mutation in codon 972 in IRS-1 impairs insulin-stimulated signaling, especially along the PI 3-kinase pathway and may contribute to insulin resistance in diabetic patients. Clausen and his co-workers [25] reported that, the combination of obesity and the codon-972 variant was associated with a 50% reduction in insulin sensitivity and suggested that, the codon-972 IRS-1 gene variant may interact with obesity in the pathogenesis of common insulin-resistant disorders. On the other hand there are different studies failed to confirm the association between IRS-1 polymorphisms and type 2 diabetes [8, 26]. The PCR

amplified DNA fragment (324bp) of A6224G within Insulin receptor substrate-1 (IRS-1) gene among Saudi type 2 diabetic patients and electrophoretic banding pattern of amplified DNA fragment 324bp after digestion with *NsiI* restriction enzyme were shown in Figures (1 and 3). The insulin receptor gene *NsiI* RFLP alleles and genotype distribution in the subjects were described in Table 4. One hundred and six type 2 diabetic patients were genotyped for A6224G polymorphism. Out of them, there were 43 patients with AA genotype with prevalence 40.6%, 62 were AG genotype with prevalence 58.5%. While GG genotype was recorded with only one patient with prevalence of 0.94% Table (4). The A allele frequency was 0.7 and G allele frequency was 0.3. On the other hand among 106 patients no presence of mitochondrial tRNA^{Leu(UUR)} A to G 3243 mutation was observed. The prevalence of AA genotype was 100%. The A allele frequency was 1 and G allele frequency was 0. This finding is inconsistent with different studies among other Asian diabetic patients. Two different studies were conducted with Japanese diabetic patients to study the prevalence of mitochondrial tRNA^{Leu(UUR)} A to G 3243 mutation. Otabe and his coworkers [27] reported that it was 0.9% and it was 0.01% by [28]. In addition among Korean diabetic patients [7] demonstrated that, the prevalence of mitochondrial tRNA^{Leu(UUR)} A to G 3243 mutation was 0.02%.

CONCLUSION

In this screening of 106 type 2 diabetic Saudi patients, no patients with mitochondrial tRNA^{Leu(UUR)} A to G 3243 mutation were found. Among A6224G mutation within Insulin receptor substrate-1 (IRS-1) gene, one homozygote patient was observed. Further comprehensive studies would be needed to clarify the role of some polymorphisms in the etiology of type II diabetes. Thus, such polymorphisms could be employed as diagnostic marker of type II diabetes.

REFERENCES

1. Stoy, J., E.L. Edghill, S.E. Flanagan, H. Ye, V.P. Paz, A. Pluzhnikov, J.E. Below, M.G. Hayes, N.J. Cox, G.M. Lipkind, R.B. Lipton, S.A. Greeley, A.M. Patch, S. Ellard, D.F. Steiner, A.T. Hattersley, L.H. Philipson and G.I. Bell, 2007. Insulin gene mutations as a cause of permanent neonatal diabetes. *Proc. Natl Acad Sci. U.S.A.*, 18; 104(38): 15040-15044.
2. Wild, S., G. Roglic, A. Green, R. Sicree and H. King, 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*, 27(5): 1047-53.
3. Alqurashi, K.A., K.S. Aljabri and S.A. Bokhari, 2011. Prevalence of diabetes mellitus in a Saudi community. *Ann Saudi Med.*, 31(1): 19-23.
4. Al-Khader, A.A., 2001. Impact of diabetes in renal diseases in Saudi Arabia. *nephrol Dial Transplant*, 16: 2132-2135.
5. International Diabetes Federation, 2009. *IDF Diabetes Atlas*, 4th ed. International Diabetes Federation, 2009. Available: <http://www.diabetesatlas.org/>. Accessed 2010 July 08.
6. Alhyas, L., A. McKay, A. Balasanthiran and A. Majeed, 2011. Quality of type 2 diabetes management in the states of the Co-operation Council for the Arab States of the Gulf: a systematic review. *PLoS One*. 6(8):e22186. doi: 10.1371.
7. Lee, H.C., Y.D. Song, H.R. Li, J.O. Park, H.C. Suh, E. Lee, S. Lim, K. Kim and K. Huh, 1997. Mitochondrial gene transfer ribonucleic acid (tRNA)^{Leu(UUR)} 3243 and tRNA(Lys) 8344 mutations and diabetes mellitus in Korea. *J. Clin. Endocrinol Metab.*, 82(2): 372-4.
8. Vasudevan, R., P. Ismail, J. Stanlas and N. Shamsudin, 2009. Analysis of three genetic polymorphisms in Malaysian essential hypertensive and type 2 diabetic subjects. *African Journal of Biotechnology*, 8(10): 2069-2075.
9. Tawfeek, A., F.A. Habib and E. Saultan, 2011. Vitamin D Receptor BsmI Gene Polymorphisms and Gestational Diabetes Mellitus: A Saudi Study. *British Journal of Medicine and Medical Research*, 1(4): 459-468.
10. Al-Daghri, N.M., O. Al-Attas, M.S. Alokail, K.M. Alkharfy, H.M. Draz, C. Agliardi, A.K. Mohammed, F.R. Guerini and M. Clerici, 2012. Vitamin D receptor gene polymorphisms and HLA DRB1*04 cosegregation in Saudi type 2 diabetes patients. *J. Immunol.*, 1; 188(3): 1325-32.
11. Jiffri, E., 2012. Association of the UCP2 45-bp insertion/deletion polymorphism with diabetes type 2 and obesity in Saudi population. *Egyptian Journal of Medical Human Genetics*, 13(3): 257-262.
12. Alharbi, K., I. Khan, N. Al-Daghri, A. Munshi, V. Sharma, A. Mohammed, K. Wani, Y. Al-Sheikh, M.S. Al-Nbaheen, M. Ansari and R. Syed, 2013. ABCA1 C69T gene polymorphism and risk of type 2 diabetes mellitus in a Saudi population. *J. Biosci.*, 38(5): 893-897.
13. El-Badrawy, E.I., Z. Ibrahim, A. Abdel Aziz, M. Mahmoud, M. Kamel, G. Shehab and A. Kamal, 2013. Association of Vitamin D Receptors Genes Polymorphism (Apa I and Taq I) with type 1 diabetes in Saudi. Arabia (KSA). *Life Science Journal*, 10(3): 1555-1562.
14. Al-Harithy, R. and N. Al-Zahrani, 2013. Leptin Receptor RS1137101 Variant is Risk Factor for Obesity and Type II Diabetes in Saudi Adult Women. *International Journal of Medical Sciences and Health Care*, 1(7): 14-20.
15. Cortassa, S., M.A. Aon, E. Marban, R.L. Winslow and B. O'Rourke, 2003. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. *Biophys. J.*, 84: 2734-2755.
16. Ye, Z., C. Gillson, M. Sims, K.T. Khaw, M. Plotka, J. Poulton, C. Langenberg and N.J. Wareham, 2013. The association of the mitochondrial DNA OriB variant (16184-16193 polycytosine tract) with type 2 diabetes in European populations. *Diabetologia*, 56(9): 1907-13.
17. Soini, H., J. Moilanen, T. Kerälä, S. Finnälä and K. Majamaa, 2013. Mitochondrial DNA variant m. 15218A > G in Finnish epilepsy patients who have maternal relatives with epilepsy, sensorineural hearing impairment or diabetes mellitus. *BMC Medical Genetics*, 14: 73-83.

18. Sethumadhavan, S., J. Vasquez-Vivar, R.Q. Migrino, L. Harmann, H.J. Jacob and J. Lazar, 2012. Mitochondrial DNA variant for complex I reveals a role in diabetic cardiac remodeling. *J. Biol. Chem.*, 22; 287(26): 22174-82.
19. Chien, M.C., W.T. Huang, P.W. Wang, C.W. Liou, T.K. Lin, C.J. Hsieh and S.W. Weng, 2012. Role of mitochondrial DNA variants and copy number in diabetic atherogenesis. *Genetics and Molecular Research*, 11(3): 3339-3348.
20. Gupta, B.B.P., 1997. Mechanism of insulin action. *Curr. Sci.*, 73: 993-1003.
21. Almind, K., 1993. Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. *Lancet*, 342: 828-832.
22. Kovacs, P., R.L. Hanson, Y.H. Lee, X. Yang, S. Kobes, P.A. Permana, C. Bogardus and L.J. Baier, 2003. The role of insulin receptor substrate-1 gene (IRS1) in type 2 diabetes in Pima Indians. *Diabetes*, 52(12): 3005-9.
23. Laakso, M., M. Malkki, P. Kekäläinen, J. Kuusisto and S.S. Deeb, 1994. insulin receptor substrate-1 variants in non-insulin-dependent diabetes. *J. Clin. Invest.* 1994 September, 94(3): 1141-1146.
24. Almind, K., G. Inoue, O. Pedersen and C. Kahn, 1996. A Common Amino Acid Polymorphism in Insulin Receptor Substrate-1 Causes Impaired Insulin Signaling Evidence from Transfection Studies. *The Journal of Clinical Investigation*, 97(11): 2569-2575.
25. Clausen, J.O., T. Hansen, C. Bjorbaek, S.M. Echwald, S.A. Urhammer, S. Rasmussen, C.B. Andersen, L. Hansen, K. Almind and K. Winther, 1995. Insulin resistance: interactions between obesity and a common variation of insulin receptor substrate-1. *Lancet*, 346: 397-402.
26. Celi, F.S., C. Negri, K. Tanner, N. Raben, F. DePablo, A. Rovira, L.F. Pallardo, P. Martin-Vaquero, M.P. Stern, B.D. Mitchell and A.R. Shuldiner, 2000. Molecular scanning for mutations in the insulin receptor substrate-1 (IRS-1) gene in Mexican Americans with Type 2 diabetes mellitus. *Diabetes Metab Res. Rev.*, 16(5): 370-377.
27. Otabe, S., H. Sakura, K. Shimokawa, Y. Mori, H. Kadowaki, K. Yasuda, K. Nonaka, R. Hagura, Y. Akanuma and Y. Yazaki, 1994. The high prevalence of the diabetic patients with a mutation in the mitochondrial gene in Japan. *J. Clin. Endocrinol. Metab.*, 79(3): 768-71.
28. Ohkubo, K., A. Yamano, M. Nagashima, Y. Mori, K. Anzai, Y. Akehi, R. Nomiyama, T. Asano, A. Urae and J. Ono, 2001. Mitochondrial gene mutations in the tRNA(Leu(UUR)) region and diabetes: prevalence and clinical phenotypes in Japan. *Clin Chem.*, 47(9): 1641-8.